(Q81585317)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

review article

1 reference

title

[Psychiatric disorders during treatment of chronic hepatitis C] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Laurent Castéra

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Chantal Henry

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Patrice Couzigou

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

publication date

1 February 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

Gastroenterologie Clinique et Biologique

10 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

123-133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Side effects of alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Hepatitis C, interferon alfa, and depression

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Psychiatric complications of long-term interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Side effects of high-dose interferon therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Incidence of interferon alfa-induced depression in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Therapy of hepatitis C: interferon alfa-n1 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Morbidity of chronic hepatitis C as seen in a tertiary care medical center

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy. A prospective study in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Neurotoxic and other side effects of high-dose interferon in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Interferon Alpha-Induced Depression in Chronic Hepatitis C Patients: Comparison between Different Types of Interferon Alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Interferon alpha (IFNalpha) and psychiatric syndromes: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Manic episodes in two patients treated with interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Suicide associated with alfa-interferon therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

A case of persistent manic depressive illness induced by interferon-alfa in the treatment of chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Mania Induced by Withdrawal of Treatment With Interferon Alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Hepatitis C, alpha interferon, anxiety and depression disorders: a prospective study of 71 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Fatigue, depression and chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

A SELF-RATING DEPRESSION SCALE

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

The hysterical personality. An attempt at validation with the MMPI.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

The hospital anxiety and depression scale

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Psychometric assessment of depression in an elderly general medical population. Over- or underassessment?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

A diagnostic interview: the schedule for affective disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Hepatitis C and depression

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Depression, fatigue, and functional disability in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Emotional distress in chronic hepatitis C patients not receiving antiviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Psychiatric disorders among veterans with hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

The impact of diagnosis of hepatitis C virus on quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Psychosocial factors associated with perceived disease severity in patients with chronic hepatitis C: relationship with information sources and attentional coping styles

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Central nervous system toxicity of interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Electroencephalographic abnormalities in interferon encephalopathy: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Enhancement of immobility in mouse forced swimming test by treatment with human interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Five cases of interferon-alpha-induced depression treated with antidepressant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Successful treatment of interferon alfa-induced mood disorder with nortriptyline

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Letters of condolence

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

An open-label trial of citalopram for major depression in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2805%2980714-6

7 January 2021

10.1016/S0399-8320(05)80714-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15795658%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference